Bedinvetmab (Librela) is a fully canine recombinant monoclonal antibody that binds nerve growth factor (NGF), preventing NGF from engaging its TrkA and p75 neurotrophin receptor (p75NTR) receptors and thereby reducing peripheral sensitization and pain signaling in osteoarthritic joints. NGF is elevated in the osteoarthritic joints of dogs and, following noxious stimulation, drives peripheral sensitization, neurogenic inflammation, and recruitment of additional proinflammatory mediators through TrkA signaling on peripheral nerves, immune cells, endothelial cells, synoviocytes, and chondrocytes. FDA DailyMed An… Bedinvetmab selectively binds NGF without cross-reacting with neurotrophin-3, neurotrophin-4, or brain-derived neurotrophic factor. FDA DailyMed An…
The approved dose is 0.5–1.0 mg/kg SC once monthly, with effectiveness established after a minimum of two doses administered one month apart. FDA DailyMed An…+1 After the first dose, bedinvetmab has a mean half-life of 19.1 days (SD 8.3 days). Veterinary Anae…
Efficacy data from two pivotal placebo-controlled field studies are consistent. In the EU registration study, treatment success on the Canine Brief Pain Inventory (CBPI) at Day 28 was 43.5% for bedinvetmab versus 16.9% for placebo. Veterinary Anae… Success rates continued to rise with repeated monthly dosing, reaching 50.8% at Day 56 and 48.2% at Day 84 in the bedinvetmab group, while the placebo group remained below 25% at all time points. Veterinary Anae… In the US registration study, Day 28 CBPI treatment success was 47.4% for bedinvetmab versus 36.6% for placebo, with a number needed to treat of 9.3 at Day 28 improving to 4.3 by Day 84 with continued monthly dosing. Veterinary Anae… Bedinvetmab produced significant improvement over placebo on all three CBPI components — pain interference score, pain severity score, and quality of life — in both studies. Veterinary Anae…+1
Bedinvetmab is non-inferior to grapiprant by objective force plate gait analysis. CBPI treatment success at Day 42 was 68.8% for bedinvetmab and 56.3% for grapiprant, with the upper bound of the 90% confidence interval (18.8%) falling below the pre-specified non-inferiority margin of 21.25%, supporting both agents as appropriate first-line treatments for osteoarthritis pain. Scientific Repo…
Safety across all controlled studies has been favorable. Adverse health events occurred at similar frequencies between bedinvetmab and placebo groups and were considered typical for an osteoarthritic dog population rather than treatment-related. Veterinary Anae…+1 Anti-NGF monoclonal antibodies as a class do not appear to be associated with organ-specific adverse effects in dogs, though full post-market safety characterization is ongoing. WSAVA Global Gu…
Sustained efficacy has been demonstrated for up to 9 months of monthly dosing in the continuation phase of the EU study, with no attenuation of effect over time. Veterinary Anae… The WSAVA Pain Guidelines recognize bedinvetmab as appropriate first-line therapy for osteoarthritis pain in dogs, with a single subcutaneous injection providing at least one month of pain relief. WSAVA Global Gu…
| Parameter | EU Study Veterinary Anae… | US Study Veterinary Anae… |
|---|---|---|
| Dose | 0.5–1.0 mg/kg SC q28d | 0.5–1.0 mg/kg SC q28d |
| Day 28 treatment success (bedinvetmab) | 43.5% | 47.4% |
| Day 28 treatment success (placebo) | 16.9% | 36.6% |
| Day 84 treatment success (bedinvetmab) | 48.2% | Continued improvement |
| NNT at Day 28 | Not reported | 9.3 |
| NNT at Day 84 | Not reported | 4.3 |
| Half-life | Not reported | 19.1 days (SD 8.3) |
| Adverse events | Similar to placebo | Similar to placebo |
Would you like guidance on combining bedinvetmab with NSAIDs or other analgesics in dogs with inadequate single-agent pain control?